CONMED vs Glaukos
CONMED reported revenue of $1.4 billion in fiscal 2025, 2.7 times Glaukos' $507 million in fiscal 2025. CONMED's revenue grew 5.2% in its latest year, and Glaukos' grew 32.3%. CONMED had an operating margin of 7.5%, against -39.3% at Glaukos. Free cash flow was $151 million at CONMED and −$22 million at Glaukos.
Side by side
| CONMED | Glaukos | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.4B | $507M |
| Revenue growth | 5.2% | 32.3% |
| Revenue growth a year, last 5 years | 9.8% | 17.7% |
| Gross margin | 54.6% | 55.7% |
| Operating margin | 7.5% | −39.3% |
| Net margin | 3.4% | −37.0% |
| Free cash flow | $151M | −$22M |
| Free cash flow margin | 11.0% | −4.4% |
| Return on capital | 3.7% | — |
| Net debt to EBITDA | 5.1x | — |
| Dividends and buybacks | $25M | $0M |
| Change in diluted share count | −0.0% | 8.4% |
| Last close | $47.68 | $178.27 |
| P/E at the last close | 31.6× | — |
| Insider trades, last 12 months | sold $161,091 | sold $69.1 million |
| Piotroski F-score | 6 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CONMEDGlaukos
Operating margin
Percent of revenue
CONMEDGlaukos
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CONMEDGlaukos